Prévia do material em texto
Report Cellular Phenotypes in Hu man iPSC-Derived Neurons from a Genetic Model of Autism Spectrum Disorder Graphical Abstract Highlights d Cellular model of NDDs established using hiPSCs from 16pdel and 16pdup carriers d Opposing neuronal size phenotype may model macro- and microcephaly d Synaptic impairment in 16pdel and 16pdup neurons may reflect behavioral features d Functional compensation observed in 16pdup compared with 16pdel neurons Deshpande et al., 2017, Cell Reports 21, 2678–2687 December 5, 2017 ª 2017 The Authors. https://doi.org/10.1016/j.celrep.2017.11.037 Authors Aditi Deshpande, Smita Yadav, Dang Q. Dao, ..., Yuh-Nung Jan, Erik M. Ullian, Lauren A. Weiss Correspondence lauren.weiss@ucsf.edu In Brief Deshpande et al. show that neurons derived from individuals harboring neurodevelopmental disorders caused by the 16p11.2 deletion or duplication manifest contrasting cellular phenotypes that may underlie the macro- or microcephaly observed in carriers, respectively. Comparable functional changes in deletion- and duplication- derived neurons suggest similar mechanisms underlying common clinical features, like autism. mailto:lauren.weiss@ucsf.edu https://doi.org/10.1016/j.celrep.2017.11.037 http://crossmark.crossref.org/dialog/?doi=10.1016/j.celrep.2017.11.037&domain=pdf Cell Reports Report Cellular Phenotypes in Human iPSC-Derived Neurons from a Genetic Model of Autism Spectrum Disorder Aditi Deshpande,1,2,3 Smita Yadav,4,5,6 Dang Q. Dao,7 Zhi-Yong Wu,1,2,3 Kenton C. Hokanson,7,8 Michelle K. Cahill,8 Arun P. Wiita,9 Yuh-Nung Jan,4,5,6 Erik M. Ullian,7,8 and Lauren A. Weiss1,2,3,10,* 1Department of Psychiatry, University of California, San Francisco, San Francisco, CA, 94143, USA 2Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, 94143, USA 3Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94143, USA 4Howard Hughes Medical Institute 5Department of Physiology 6Department of Biochemistry and Biophysics University of California, San Francisco, San Francisco, CA 94158, USA 7Department of Ophthalmology, University of California, San Francisco, CA 94143, USA 8Neuroscience Graduate Program, University of California, San Francisco, CA 94158, USA 9Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94107, USA 10Lead Contact *Correspondence: lauren.weiss@ucsf.edu https://doi.org/10.1016/j.celrep.2017.11.037 SUMMARY A deletion or duplication in the 16p11.2 region is associated with neurodevelopmental disorders, including autism spectrum disorder and schizo- phrenia. In addition to clinical characteristics, car- riers of the 16p11.2 copy-number variant (CNV) man- ifest opposing neuroanatomical phenotypes—e.g., macrocephaly in deletion carriers (16pdel) and microcephaly in duplication carriers (16pdup). Using fibroblasts obtained from 16pdel and 16pdup car- riers, we generated induced pluripotent stem cells (iPSCs) and differentiated them into neurons to iden- tify causal cellular mechanisms underlying neurobio- logical phenotypes. Our study revealed increased soma size and dendrite length in 16pdel neurons and reduced neuronal size and dendrite length in 16pdup neurons. The functional properties of iPSC- derived neurons corroborated aspects of these con- trasting morphological differences that may underlie brain size. Interestingly, both 16pdel and 16pdup neurons displayed reduced synaptic density, sug- gesting that distinct mechanisms may underlie brain size and neuronal connectivity at this locus. INTRODUCTION The increasing prevalence of autism spectrum disorder (ASD) highlights the importance of identifying biomarkers and thera- peutic targets. This complex neurodevelopmental disorder (NDD) is characterized by repetitive or stereotypic behaviors as well as communication and social deficits (American Psychiatric Association, 2013). However, the neurobiological mechanisms underlying the pathology of ASD are not well understood. Of the known genetic etiologies for ASD, rare and recurrent 2678 Cell Reports 21, 2678–2687, December 5, 2017 ª 2017 The Au This is an open access article under the CC BY license (http://creative copy-number variants (CNVs) have emerged as highly penetrant risk factors (Malhotra and Sebat, 2012). The 16p11.2 CNV is an �600-kb locus harboring 29 annotated genes, most of which are highly expressed in the brain; deletion or duplication of this locus is associated with ASD (Weiss et al., 2008). The levels of mRNA expression of 16p11.2 genes correspond to copy number in human lymphoblastoid cell lines (LCLs), in induced pluripotent stem cells (iPSCs), and in the mouse brain; i.e., reduced in dele- tion carriers (16pdel) and increased in duplication carriers (16pdup) (Blumenthal et al., 2014; Tai et al., 2016). Studies in an- imal models and transcriptome analyses in LCLs have identified genes in the region involved in synaptogenesis, chromatin modulation, and ciliary function (Blumenthal et al., 2014; Luo et al., 2012; Migliavacca et al., 2015). In addition to ASD, the 16p11.2 deletion is a risk factor for developmental delay (DD), language impairment, and epilepsy, whereas the reciprocal duplication predisposes carriers to schizophrenia, bipolar disor- der, DD, and seizures (Kumar et al., 2008; McCarthy et al., 2009; Rosenfeld et al., 2010; Shinawi et al., 2010; Weiss et al., 2008). Despite common behavioral symptoms, including ASD, 16p11.2 CNV carriers manifest opposing neuroanatomical phe- notypes, such as macrocephaly in 16pdel and microcephaly in 16pdup (Qureshi et al., 2014). Interestingly, head circumference or brain size changes occur in additional genetic etiologies of ASD and NDDs. For example, loss-of-function mutations in the PTEN gene have been shown to result in extreme macrocephaly and ASD (Butler et al., 2005). Disruptive mutations in CHD8 are associated with ASD and macrocephaly (Bernier et al., 2014). Other CNVs, such as the 1q21.1 duplication, predispose to ASD and macrocephaly in addition to intellectual disability (ID) and schizophrenia (Mef- ford et al., 2008; Milone et al., 2016). In contrast, microcephaly is observed in carriers with mutations inDYRK1A along with a pre- disposition for ID, ASD, and seizures (Ji et al., 2015). Although both macrocephaly and microcephaly can be associated with ASD, studies demonstrating that the same gene (or pathway) can cause both macrocephaly and microcephaly (e.g., via thors. commons.org/licenses/by/4.0/). mailto:lauren.weiss@ucsf.edu https://doi.org/10.1016/j.celrep.2017.11.037 http://crossmark.crossref.org/dialog/?doi=10.1016/j.celrep.2017.11.037&domain=pdf http://creativecommons.org/licenses/by/4.0/ gain- or loss-of-function mutations) are lacking. Thus, the 16p11.2 CNV appears to be uniquely poised to investigate whether a single cellular mechanism, dysregulated in opposite directions, could be responsible for opposing brain size pheno- types. Furthermore, the relationship between brain growth mechanisms and ASD-relevant functional characteristics could be applicable to a range of ASD risk factors. At the cellular level, brain overgrowth or undergrowth often result from dysregulation of early developmental pathways in neural progenitor cells (NPCs). The cellular processes that can be disrupted are cell proliferation and apoptosis, cell growth, or differentiation (Groszer et al., 2001; Homem et al., 2015). We hypothesize that perturbation of one or more of these cellular processes may underlie the brain growth phenotype in 16p11.2 CNV carriers, given that the CNV harbors genes known to manifest early neurobiological phenotypes when dysregulated. Noteworthy examples are MAPK3, a key component of the Ras/mitogen-activated protein kinase (MAPK) pathway which regulates multiple processes, including proliferation and differ- entiation; TAOK2, a kinase essential for dendrite and spine morphogenesis;and KCTD13, a ubiquitin ligase family member shown to affect head size by altering NPC proliferation and apoptosis in a dose-dependent manner in zebrafish (de Anda et al., 2012; Golzio and Katsanis, 2013; Pucilowska et al., 2015; Yadav et al., 2017). However, the cellular mechanisms in 16p11.2 CNV carriers underlyingmacro- or microcephaly remain unknown. Further, it is unclear whether behavioral symptoms common to these CNVs are a direct consequence of the same mechanism underlying differences in brain size. To test whether early developmental processes underlie the brain size phenotype, we generated iPSCs from fibroblasts of 16pdel and 16pdup carriers and controls. We differentiated them into forebrain cortical neurons. We assessed proliferation by examining cell cycle markers, cell growth by measuring soma size, and differentiation by measuring dendritic growth and synaptic development. Finally, we assessed the electro- physiological properties of iPSC-derived neurons to determine whether they reflect the observed morphological differences and assessed synaptic development to determine whether the same mechanism contributing to brain size may also influence functional properties. RESULTS Generation of iPSCs from 16p11.2 CNV Carriers and Differentiation into NPCs The 16p11.2 CNV carrier-derived iPSCs were comparable with control iPSCs with respect to stem cell marker expression and pluripotency (Figures 1Aand1B; FiguresS1Aand1B). To confirm that iPSCs retained the CNV status after reprogramming, we assessed, by qRT-PCR, the mRNA levels of selected genes spanning the 16p11.2 CNV. We found that generally the expres- sion of QPRT, MVP, KCTD13, TAOK2, ALDOA, TBX6, MAPK3, and CORO1A was decreased to about 0.3–0.5 times in 16pdel lines and increased by about 1.2–1.5 times in 16pdup lines when normalized to controls (Figure 1C; Figure S1C). We then differentiated iPSCs to forebrain cortical neurons (Zhang et al., 2001; Figure 1D). We generated NPCs from three carriers each of 16pdel and 16pdup and four controls and analyzed 2–3 clones per individual for each experiment described (Table S4). The proportion of specific forebrain NPC markers, such as PAX6 and nestin, in 16pdel, control, and 16pdup was comparable, suggesting induction of dorsal fore- brain identity (Figures 1E and 1F; Figures S2C and S2D). Quan- titative RT-PCR for selected 16p11.2 genes in NPCs generally showed the expected expression patterns; i.e., decreased in 16pdel and increased in 16pdup (Figure S2A). We then checked NPC proliferation by 5-ethynyl-20-deoxyuridine (EdU) incorpora- tion assay; the proportion of EdU+ NPCs was not significantly different in either 16pdel or 16pdup NPCs compared with con- trols after a 24-hr chase following a 4-hr EdU pulse (p = 0.56 and 1.0, respectively; Figures 1E and 1G). To assess whether the self-renewal capacity of NPCs was altered, we incubated NPCs with EdU, followed 24 hr and 48 hr later with a 1-hr pulse of bromodeoxyuridine (BrdU). We did not observe a statistically significant difference in EdU-only (cells that exited the cell cycle) in the 24-hr (16pdel, p = 0.53; 16pdup, p = 0.79) or 48-hr (16pdel, p = 0.19; 16pdup, p = 1.0) paradigm. The proportion of EdU+/ BrdU+ double-labeled cells (that reentered the cell cycle) was also not significantly altered between 16pdel, control, and 16pdup NPCs at 24 hr (16pdel, p = 0.29; 16pdup, p = 0.25) or 48 hr (16pdel, p = 0.56; 16pdup, p = 0.56; Figures S2B and S2E–S2J). Because the proliferation rate of 16pdel and 16pdup NPCs was unchanged compared with controls, it is unlikely to account for the opposing brain size phenotype in human carriers. 16p11.2 CNV Carrier-Derived Neurons Show Altered Morphometric Characteristics Wenext investigatedwhether neuronmorphologymay contribute to brain size.We plated the 16pdel, control, and 16pdupNPCs for differentiation into neurons about 4 weeks after neural induction. For visualization, we transduced the cultures with a lentivirus expressing GFP under the neuron-specific synapsin promoter (SynGFP). 3 weeks post-differentiation (wpd), the 16pdel SynGFP+ neurons showed neuronal hypertrophy compared with controls, whereas the soma size of 16pdup neurons was reduced (16pdel, p = 3.39 3 10�5; 16pdup, p = 4.1 3 10�4; Figures S3A and S3B). At 6 wpd, the soma size of 16pdel neurons was significantly larger (p = 7.723 10�6), whereas that of 16pdup neurons was significantly smaller (p = 6.11 3 10�12) compared with control neurons (Figures 2A and 2B). This prompted us to assess whether the change in neuronal size is restricted to the soma or is also reflected in other morphological features. Our an- alyses revealed that 16pdel neurons have increased total dendrite length (p = 4.523 10�5) andmore extensive dendritic ar- bors (pneurons was not significantly decreased (p = 0.38; Figures S3C–S3F). The opposing soma size phenotype was robustly maintained through 14 wpd (Figure 2E). qRT-PCR for selected 16p11.2 genes in 6-wpd neurons also generally correlated with copy number; i.e., decreased in 16pdel carriers and increased in 16pdup carriers (Figure S4A). Thus, neurons generated from 16pdel- and 16pdup-derived NPCs, specifically excitatory neurons, manifest overt and opposing differences in soma size and total dendrite length that may contribute to head circumference phenotypes observed in carriers. Intrinsic Excitability of 16pdel Carrier-Derived Neurons Corroborates the Cell Size Phenotype The intrinsic properties of neurons can be affected by cell size and morphology. Our results showing altered soma size associ- ated with 16p11.2 CNV led us to examine whether this translates to altered electrical properties and, eventually, neuron function. We performed patch-clamp electrophysiology at 14 wpd on SynGFP+ 16pdel, control, and 16pdup neurons. We examined the ability of the 16p11.2 CNV carrier-derived neurons to fire ac- pr Th co im wh di tro co th re in sig at p sh co th pl po sa sig Ho (p Cell Repo tion potentials (APs), the bona fide physi- ological marker of neurons. When in- jected with current to evoke APs, 16pdel neurons required nearly twice as much current as control neurons to fire the first AP (p = 2.02 3 10�3; Figures 3A and 3B), and they fired far fewer APs at any particular current step than either of the other two groups (pin synaptic function, we recorded miniature excitatory postsynaptic currents (mEPSCs) in 8 to 9 wpd CaMKIIaGFP+ neurons. We did not observe a significant difference in the kinetics (16pdel, p = 0.29; 16pdup, p = 0.88) or frequency (16pdel, p = 0.46; 16pdup, p = 0.33) of the mEPSCs in 16pdel and 16pdup neurons compared with controls (Figures S4F and S4H). However, the amplitude of mEPSCs was signifi- cantly increased in both 16pdel and 16dup neurons (16pdel, psynaptic function andmatu- ration are warranted. Although we observed that reduced soma size was corrobo- rated by a trend of reduced Cm in 16pdup neurons, other intrinsic excitability parameters, such as AP firing or Rinp, did not deviate from controls. This suggests either a compensation for morpho- logical changes or a subtle phenotype that would not be readily observed in our model system. For example, the upregulation in potassium conductance may serve to preserve a normal amount of potassium flux, which helps preserve excitability, indicative of compensation by 16pdup neurons for their reduced size. How- ever, consistent with the synaptic defects in 16pdel neurons, 16pdup neurons showed a reduced synaptic density and increased mEPSC amplitude. Thus, although 16pdup neurons may retain the capacity to rebalance membrane conductance to preserve excitability, they exhibit substantial deficits in synap- tic connectivity and function. Themore evident cellular phenotypes observed in 16pdel neu- rons compared with 16pdup neurons may result from the more dramatic fold change in gene expression for deletion (0.53) compared with duplication (1.53) CNVs. Alternatively, it may result from under-expression generally being more impactful than overexpression because having less of a critical protein could be more difficult to overcome than excess protein (e.g., when other limiting factors exist). This pattern may underlie the failure of the hypertrophic 16pdel neurons to functionally compensate for increased size (e.g., AP firing), resulting in strik- ing physiological defects that affect the formation and function of neural networks. The hypotrophic 16pdup neurons, on the other hand, are capable of homeostatically regulating their excitability. These findings at the cellular level are consistent with clinical fea- tures, given that neurological symptoms, although incompletely penetrant, aremore common among 16pdel carriers than among 16pdup carriers, who often show milder or no clinical features (Golzio and Katsanis, 2013; Steinman et al., 2016). Moreover, the cellular phenotypes were extremely consistent in each group (across individuals and clones), supporting the robustness of our conclusions despite inter-individual variation. In summary, our iPSC-derived model of 16p11.2 CNVs provides evidence of causal neuronal and synaptic phenotypes that might contribute to neuropathology associated with 16p11.2 CNVs, are present in a system amenable to manipulation, and, in future studies, will be important in establishing a gene/pathway-phenotype correlation. EXPERIMENTAL PROCEDURES 16p11.2 CNV Carriers Skin fibroblasts of three 16p11.2 deletion and three duplication carriers were obtained from the Simons Variation in Individuals Project (VIP) and used for re- programming to iPSCs (Simons VIP Consortium, 2012). Fibroblasts of control individuals were obtained by punch biopsies using published protocols (Rooney et al., 2016). The control line BJ4 was a kind gift from the Hsiao lab (Matsumoto et al., 2013). Carrier and control lines are described in Table S1. All human research was performed in accordance with institutional review board (IRB) and Committee on Human Research codes of practice (IRB proto- cols 10-03304, 10-01426, and 10-02794). Generation of iPSCs Using Episomal Vectors Fibroblasts were cultured in DMEM with 10% fetal bovine serum (FBS) (Life Technologies) and reprogramed to iPSCs with the episomal plasmids pCXLE-hOct3/4-shp53-F, pCXLE-hSox2-Klf4, and pCXLE-hcmyc-Lin28 (Addgene) using published protocols (Okita et al., 2011). Briefly, cells were electroporated with 3 mg plasmid mixture using the Neon transfection device (Invitrogen) according to the manufacturer’s protocol (1, 650 V, 10 ms width, and 3 pulses). Transfected cells were plated on mitomycin C-treated mouse embryonic fibroblasts (MEFs, Millipore) in human embryonic stem (hES) medium: knockout DMEM/F-12, 13 knockout serum replacement, 1% non- essential amino acids, 1% penicillin/streptomycin (Life Technologies) with bFGF. The iPSC colonies were picked manually after 2 weeks and transferred to MEF feeders in hES medium. After a few passages on MEFs, iPSCs were transferred to plates coated with Matrigel (BD Biosciences) and maintained in mTeSR-1 medium (Stem Cell Technologies). All experiments were per- formed with 2–3 independent iPSC clones per line. Characterization of iPSCs from 16p11.2 CNV Carriers Induced PSCs were stained for nanog, OCT4, SOX2, and SSEA-4. For pluripotency analysis, iPSCs were allowed to differentiate spontaneously in mTeSR-1 medium or randomly differentiated using the Human Pluripotent Stem Cell Functional Identification Kit (SC027, R&D Systems) and stained for markers of the three germ layers. All iPSCs generated cells of all three germ layers, as assessed by positive immunoreactivity for b-III-tubulin for ectoderm, smooth muscle actin for mesoderm, and SOX17 for endoderm. For the array comparative genomic hybridization (CGH), DNA was extracted using the QIAamp DNA Blood Mini Kit (QIAGEN) according to the manufac- turer’s protocol and eluted in nuclease-free water. Eluted DNA was processed for analysis by Illumina CytoSNP 850K array according to the manufacturer’s protocol. Data were processed, and CNV calls were generated with BlueFuse Multi Software v4.2 (Illumina). CNV calls by SNP array were re- ported using standard clinical thresholds in the University of California San Francisco (UCSF) Clinical Cytogenetics Laboratory, including annotation of any CNVs > 200 kb. Interpretation of clinical significance was done according to standard American College of Medical Genetics guidelines (Kearney et al., 2011). See Table S2 for array CGH results. Statistical Analyses All results are represented as bar or line plots using the ggplot2 library in the R 3.2.0 environment (https://www.r-project.org). Bar plots show means ± SE for the 16pdel, control, and 16pdup groups. Symbols represent all lines used in the study. Statistical significance between the groups was assessed with the Mann-Whitney-Wilcoxon signed-rank test with the wilcox.test() func- tion in R. Line plots show means ± SE for each group for repeated measure- ments. Statistical significance was calculated using repeated-measures ANOVA with post hoc Tukey’s honest significant difference (HSD) correction using the aov() and TukeyHSD() functions in R. SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures, four figures, and four tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2017.11.037. AUTHOR CONTRIBUTIONS Conceptualization, A.D. and L.A.W; Methodology, A.D., L.A.W., S.Y., D.Q.D., and E.M.U.; Investigation, A.D., S.Y., D.Q.D., Z.-Y.W., K.C.H., M.K.C., and A.P.W.; Writing – Original Draft, L.A.W. and A.D.; Writing – Review & Editing, L.A.W., A.D., S.Y., D.Q.D., Z.-Y.W., K.C.H., E.M.U., and Y.-N.J.; Funding Acquisition, L.A.W., E.M.U., and Y.-N.J. ACKNOWLEDGMENTS We thank Curtis Tom, Federico Mendoza-Camacho, Cheuk Tam, John Paul Kwok, Tracy Hyunh, and Shriya Perati for technical assistance. We also thank Dr. Edward Hsaio for kindly sharing the BJ4 iPSC line and Dr. Michela Traglia for her expertise in using the R software. We thank Michael Ho of the UCSF Clinical Cytogenetics Laboratory for processing samples for array CGH. We are grateful to all families participating in the Simons VIP. We appreciate ac- cess to phenotypic data on the SFARI Base. This work was supported by a grant from the Simons Foundation (SFARI 345471 to L.A.W. and E.M.U.). This work was funded by NIH DP2 OD007449, NIH R21 MH105745, and a CIRM Bridges grant to CCSF (#TB1-01188) and IMHRO (to L.A.W.). A.D. was supported by the Autism Speaks Meixner Postdoctoral Fellowship in Translational Research (#9224). S.Y. was supported by NIH Pathway to Inde- pendence Grant 5K99MH108648-02. D.Q.D. and K.C.H.were funded by NIH T32 Training Grant EY007120. E.M.U. was funded by a Research to Prevent Cell Reports 21, 2678–2687, December 5, 2017 2685 https://www.r-project.org https://doi.org/10.1016/j.celrep.2017.11.037 Blindness Unrestricted Grant, Allen Family Foundation Distinguished Investi- gator Award and NEI EY002162. Received: January 12, 2017 Revised: September 1, 2017 Accepted: November 10, 2017 Published: December 5, 2017 REFERENCES American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Arlington, VA: Americal Psychiatric Publishing). Benavides-Piccione, R., Dierssen, M., Ballesteros-Yáñez, I., Martı́nez de Lagrán, M., Arbonés, M.L., Fotaki, V., DeFelipe, J., and Elston, G.N. (2005). Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol. Dis. 20, 115–122. Bernier, R., Golzio, C., Xiong, B., Stessman, H.A., Coe, B.P., Penn, O., Wither- spoon, K., Gerdts, J., Baker, C., Vulto-van Silfhout, A.T., et al. (2014). Disrup- tive CHD8mutations define a subtype of autism early in development. Cell 158, 263–276. Bizzotto, S., and Francis, F. (2015). Morphological and functional aspects of progenitors perturbed in cortical malformations. Front. Cell. Neurosci. 9, 30. Blumenthal, I., Ragavendran, A., Erdin, S., Klei, L., Sugathan, A., Guide, J.R., Manavalan, P., Zhou, J.Q., Wheeler, V.C., Levin, J.Z., et al. (2014). Transcrip- tional consequences of 16p11.2 deletion and duplication in mouse cortex and multiplex autism families. Am. J. Hum. Genet. 94, 870–883. Butler, M.G., Dasouki, M.J., Zhou, X.-P., Talebizadeh, Z., Brown, M., Takaha- shi, T.N., Miles, J.H., Wang, C.H., Stratton, R., Pilarski, R., and Eng, C. (2005). Subset of individuals with autism spectrum disorders and extreme macroce- phaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 42, 318–321. Costa, V., Aigner, S., Vukcevic, M., Sauter, E., Behr, K., Ebeling, M., Dunkley, T., Friedlein, A., Zoffmann, S., Meyer, C.A., et al. (2016). mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis. Cell Rep. 15, 86–95. de Anda, F.C., Rosario, A.L., Durak, O., Tran, T., Gräff, J., Meletis, K., Rei, D., Soda, T., Madabhushi, R., Ginty, D.D., et al. (2012). Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex. Nat. Neurosci. 15, 1022–1031. Fotaki, V., Dierssen, M., Alcántara, S., Martı́nez, S., Martı́, E., Casas, C., Visa, J., Soriano, E., Estivill, X., and Arbonés, M.L. (2002). Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 22, 6636–6647. Gilmore, E.C., and Walsh, C.A. (2013). Genetic causes of microcephaly and lessons for neuronal development. Wiley Interdiscip. Rev. Dev. Biol. 2, 461–478. Golzio, C., and Katsanis, N. (2013). Genetic architecture of reciprocal CNVs. Curr. Opin. Genet. Dev. 23, 240–248. Golzio, C., Willer, J., Talkowski, M.E., Oh, E.C., Taniguchi, Y., Jacquemont, S., Reymond, A., Sun, M., Sawa, A., Gusella, J.F., et al. (2012). KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature 485, 363–367. Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A., Zack, J.A., Kornblum, H.I., Liu, X., and Wu, H. (2001). Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294, 2186–2189. Habela, C.W., Song, H., and Ming, G.-L. (2016). Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons. Mol. Cell. Neu- rosci. 73, 52–62. Homem, C.C.F., Repic, M., and Knoblich, J.A. (2015). Proliferation control in neural stem and progenitor cells. Nat. Rev. Neurosci. 16, 647–659. Ji, J., Lee, H., Argiropoulos, B., Dorrani, N., Mann, J., Martinez-Agosto, J.A., Gomez-Ospina, N., Gallant, N., Bernstein, J.A., Hudgins, L., et al. (2015). DYRK1A haploinsufficiency causes a new recognizable syndrome with micro- 2686 Cell Reports 21, 2678–2687, December 5, 2017 cephaly, intellectual disability, speech impairment, and distinct facies. Eur. J. Hum. Genet. 23, 1473–1481. Kearney, H.M., Thorland, E.C., Brown, K.K., Quintero-Rivera, F., and South, S.T.; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee (2011). American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitu- tional copy number variants. Genet. Med. 13, 680–685. Kolli, S., Zito, C.I., Mossink, M.H., Wiemer, E.A.C., and Bennett, A.M. (2004). The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J. Biol. Chem. 279, 29374–29385. Kumar, V., Zhang, M.-X., Swank, M.W., Kunz, J., and Wu, G.-Y. (2005). Regu- lation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 25, 11288–11299. Kumar, R.A., KaraMohamed, S., Sudi, J., Conrad, D.F., Brune, C., Badner, J.A., Gilliam, T.C., Nowak, N.J., Cook, E.H., Jr., Dobyns, W.B., and Christian, S.L. (2008). Recurrent 16p11.2 microdeletions in autism. Hum. Mol. Genet. 17, 628–638. Kwon, C.H., Zhu, X., Zhang, J., Knoop, L.L., Tharp, R., Smeyne, R.J., Eberhart, C.G., Burger, P.C., and Baker, S.J. (2001). Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat. Genet. 29, 404–411. Luo, R., Sanders, S.J., Tian, Y., Voineagu, I., Huang, N., Chu, S.H., Klei, L., Cai, C., Ou, J., Lowe, J.K., et al. (2012). Genome-wide transcriptome profiling re- veals the functional impact of rare de novo and recurrent CNVs in autism spec- trum disorders. Am. J. Hum. Genet. 91, 38–55. Malhotra, D., and Sebat, J. (2012). CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148, 1223–1241. Matsumoto, Y., Hayashi, Y., Schlieve, C.R., Ikeya, M., Kim, H., Nguyen, T.D., Sami, S., Baba, S., Barruet, E., Nasu, A., et al. (2013). Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J. Rare Dis. 8, 190. McCarthy, S.E., Makarov, V., Kirov, G., Addington, A.M., McClellan, J., Yoon, S., Perkins, D.O., Dickel, D.E., Kusenda, M., Krastoshevsky, O., et al.; Well- come Trust Case Control Consortium (2009). Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 41, 1223–1227. Mefford, H.C., Sharp, A.J., Baker, C., Itsara, A., Jiang, Z., Buysse, K., Huang, S., Maloney, V.K., Crolla, J.A., Baralle, D., et al. (2008). Recurrent rearrange- ments of chromosome 1q21.1 and variable pediatric phenotypes. N. Engl. J. Med. 359, 1685–1699. Migliavacca, E., Golzio, C., Männik, K., Blumenthal, I., Oh, E.C., Harewood, L., Kosmicki, J.A., Loviglio, M.N., Giannuzzi, G., Hippolyte, L., et al.; 16p11.2 Eu- ropean Consortium (2015). A Potential Contributory Role for Ciliary Dysfunc- tion in the 16p11.2 600 kb BP4-BP5 Pathology. Am. J. Hum. Genet. 96, 784–796. Milone, R., Valetto, A., Battini, R., Bertini, V., Valvo, G., Cioni, G., and Sicca, F. (2016). Focal cortical dysplasia, microcephaly and epilepsy in a boy with 1q21.1-q21.3 duplication. Eur. J. Med. Genet. 59, 278–282. Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409–412. Pucilowska, J., Vithayathil, J., Tavares, E.J., Kelly, C., Karlo, J.C., and Land- reth, G.E. (2015). The 16p11.2 deletion mousemodel of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. J. Neurosci. 35, 3190–3200. Qureshi, A.Y., Mueller, S., Snyder, A.Z., Mukherjee, P., Berman, J.I., Roberts, T.P.L.,Nagarajan, S.S., Spiro, J.E., Chung, W.K., Sherr, E.H., and Buckner, R.L.; Simons VIP Consortium (2014). Opposing brain differences in 16p11.2 deletion and duplication carriers. J. Neurosci. 34, 11199–11211. Rauen, K.A. (2013). The RASopathies. Annu. Rev. Genomics Hum. Genet. 14, 355–369. Rooney, G.E., Goodwin, A.F., Depeille, P., Sharir, A., Schofield, C.M., Yeh, E., Roose, J.P., Klein, O.D., Rauen, K.A., Weiss, L.A., and Ullian, E.M. (2016). http://refhub.elsevier.com/S2211-1247(17)31674-1/sref1 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref1 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref2 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref2 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref2 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref2 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref3 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref3 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref3 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref3 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref4 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref4 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref5 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref5 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref5 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref5 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref6 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref6 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref6 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref6 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref6 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref7 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref7 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref7 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref7 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref8 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref8 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref8 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref8 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref9 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref9 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref9 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref9 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref10 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref10 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref10 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref11 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref11 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref12 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref12 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref12 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref12 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref13 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref13 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref13 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref13 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref14 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref14 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref14 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref15 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref15 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref16 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref16 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref16 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref16 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref16 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref17 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref17 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref17 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref17 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref17 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref18 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref18 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref18 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref18 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref19 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref19 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref19 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref20 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref20 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref20 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref20 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref21 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref21 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref21 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref22 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref22 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref22 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref22 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref23 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref23 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref24 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref24 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref24 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref24 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref25 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref25 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref25 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref25 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref26 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref26 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref26 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref26 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref27 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref27 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref27 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref27 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref27 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref28 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref28 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref28 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref29 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref29 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref29 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref29 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref30 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref30 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref30 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref30 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref31 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref31 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref31 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref31 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref32 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref32 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref33 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref33 Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome. J. Neurosci. 36, 142–152. Rosenfeld, J.A., Ballif, B.C., Torchia, B.S., Sahoo, T., Ravnan, J.B., Schultz, R., Lamb, A., Bejjani, B.A., and Shaffer, L.G. (2010). Copy number variations asso- ciated with autism spectrum disorders contribute to a spectrum of neurodeve- lopmental disorders. Genet. Med. 12, 694–702. Russo, F.B., Cugola, F.R., Fernandes, I.R., Pignatari, G.C., and Beltr~ao-Braga, P.C.B. (2015). Induced pluripotent stem cells for modeling neurological disor- ders. World J. Transplant. 5, 209–221. Shinawi, M., Liu, P., Kang, S.-H.L., Shen, J., Belmont, J.W., Scott, D.A., Probst, F.J., Craigen, W.J., Graham, B.H., Pursley, A., et al. (2010). Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J. Med. Genet. 47, 332–341. Simons Vip Consortium (2012). Simons Variation in Individuals Project (Simons VIP): a genetics-first approach to studyingautism spectrum and related neuro- developmental disorders. Neuron 73, 1063–1067. Steinman, K.J., Spence, S.J., Ramocki, M.B., Proud, M.B., Kessler, S.K., Marco, E.J., Green Snyder, L., D’Angelo, D., Chen, Q., Chung, W.K., et al. (2016). 16p11.2 deletion and duplication: Characterizing neurologic pheno- types in a large clinically ascertained cohort. Am. J. Med. Genet. 170, 2943– 2955. Tai, D.J.C., Ragavendran, A., Manavalan, P., Stortchevoi, A., Seabra, C.M., Erdin, S., Collins, R.L., Blumenthal, I., Chen, X., Shen, Y., et al. (2016). Engi- neeringmicrodeletions andmicroduplications by targeting segmental duplica- tions with CRISPR. Nat. Neurosci. 19, 517–522. Turrigiano, G.G., and Nelson, S.B. (2004). Homeostatic plasticity in the devel- oping nervous system. Nat. Rev. Neurosci. 5, 97–107. Varga, E.A., Pastore, M., Prior, T., Herman, G.E., andMcBride, K.L. (2009). The prevalence of PTEN mutations in a clinical pediatric cohort with autism spec- trum disorders, developmental delay, and macrocephaly. Genet. Med. 11, 111–117. Weiss, L.A., Shen, Y., Korn, J.M., Arking, D.E., Miller, D.T., Fossdal, R., Sae- mundsen, E., Stefansson, H., Ferreira, M.A., Green, T., et al.; Autism Con- sortium (2008). Association between microdeletion and microduplication at 16p11.2 and autism. N. Engl. J. Med. 358, 667–675. Williams, M.R., DeSpenza, T., Jr., Li, M., Gulledge, A.T., and Luikart, B.W. (2015). Hyperactivity of newborn Pten knock-out neurons results from increased excitatory synaptic drive. J. Neurosci. 35, 943–959. Yadav, S., Oses-Prieto, J.A., Peters, C.J., Zhou, J., Pleasure, S.J., Burlingame, A.L., Jan, L.Y., and Jan, Y.-N. (2017). TAOK2 Kinase Mediates PSD95 Stability and Dendritic Spine Maturation through Septin7 Phosphorylation. Neuron 93, 379–393. Yu, Z., Fotouhi-Ardakani, N., Wu, L., Maoui, M., Wang, S., Banville, D., and Shen, S.-H. (2002). PTEN associates with the vault particles in HeLa cells. J. Biol. Chem. 277, 40247–40252. Zhang, S.-C., Wernig, M., Duncan, I.D., Br€ustle, O., and Thomson, J.A. (2001). In vitro differentiation of transplantable neural precursors from human embry- onic stem cells. Nat. Biotechnol. 19, 1129–1133. Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C.M., and Parada, L.F. (2009). Pharmacological inhibition of mTORC1 sup- presses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J. Neurosci. 29, 1773–1783. Cell Reports 21, 2678–2687, December 5, 2017 2687 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref33 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref33 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref34 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref34 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref34 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref34 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref35 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref35 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref35 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref35 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref36 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref36 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref36 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref36 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref36 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref37 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref37 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref37 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref38 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref38 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref38 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref38 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref38 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref39 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref39 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref39 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref39 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref40 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref40 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref41 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref41 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref41 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref41 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref42 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref42 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref42 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref42 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref43 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref43 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref43 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref44 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref44 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref44 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref44 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref45 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref45 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref45 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref46 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref46 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref46 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref46 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref47 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref47 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref47 http://refhub.elsevier.com/S2211-1247(17)31674-1/sref47 Cellular Phenotypes in Human iPSC-Derived Neurons from a Genetic Model of Autism Spectrum Disorder Introduction Results Generation of iPSCs from 16p11.2 CNV Carriers and Differentiation into NPCs 16p11.2 CNV Carrier-Derived Neurons Show Altered Morphometric Characteristics Intrinsic Excitability of 16pdel Carrier-Derived Neurons Corroborates the Cell Size Phenotype Altered Synaptic Development in 16p11.2 CNV Carrier-Derived Neurons Discussion Experimental Procedures 16p11.2 CNV Carriers Generation of iPSCs Using Episomal Vectors Characterization of iPSCs from 16p11.2 CNV Carriers Statistical Analyses Supplemental Information Author Contributions Acknowledgments References